Lucid Diagnostics Inc. (LUCD)
NASDAQ (CM) NASDAQ (CM) Primary 
Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Chief Financial Officer Conference Call Participants Mark Massaro – BTIG Kyle Mikson – Canaccord Genuity Mike Matson – Needham & Company Jeremy Pearlman – Maxim Group Ross Osborn – Cantor Fitzgerald Ed Woo – Ascendiant Capital Operator Good morning and welcome to the Lucid Diagnostics First Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director, Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Mike Matson - Needham & Company Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in listen-only mode.
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.23 per share a year ago.
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Mark Massaro - BTIG Anthony Vendetti - Maxim Group Mike Matson - Needham Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Dr. Lishan Aklog - Chairman, Chief Executive Officer Dennis McGrath - Chief Financial Officer Matt Riley - Director of Investor Relations Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Mark Massaro - BTIG Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Second Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
